Q2 FY24 Financial Highlights

North America: Building Complex Gx Portfolio Leadership: 4.4% TRX volume share in U.S.1 New product sales driving DE LUPIN US growth Growing Respiratory portfolio US Sales ($mn) Rx 159 177 175 181 213 #3 #1 22.9% in the US¹ Albuterol in 48 products² Maintaining leadership Top 3 in 101 products² Q2 Q3 Q4 Q1 Q2 market share 32.8% Arfomoterol market share FY23 FY23 FY23 FY24 FY24 In generics¹ Brand + generic¹ 34% YoY 18% QoQ Q2 FY24 Key Highlights Focus on profitable growth Increasing share of complex generics in portfolio led by inhalation (>40% of sales) . Continued momentum led by investments in complex formulations, 505(b)(2) and biosimilars Upscaling portfolio to higher share of complex formulations, led by inhalation, injectables and biosimilars Strong pipeline 40+ Injectables and 20+ inhalation 53 FTFs incl. 20 exclusive FTFs • • Legacy products maintaining market share ● Note: 2. 1. IQVIA Qtr TRX Sep-23 by prescriptions IQVIA Qtr Sep-23 NSP data Continued cost optimization initiatives to improve profitability 9

View entire presentation